Cholos

Quick links to important sections

Cholos

Selected form

Method of action: Choleretic, Hepatoprotective

Treatment option: Hepatitis, Cholangitis, Cholecystitis

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cholos

What is Cholos? Identity and General Purpose

Property Description
Active ingredient Rosae Pingue Fructuum Extract (Rosehip Extract)
Form Extract (Oral)
Pharmacological class Hypolipidemic agent / Phytomedicine
General purpose Supports cholesterol balance and lipid metabolism
Origin Natural, Plant-derived (Rosa genus)

What Type of Medicine is Cholos? Identity and Origin

Cholos is a phytopreparation, or herbal medicine, classified as a natural, plant-derived product. Its active component is the Rosae Pingue Fructuum Extract, commonly known as Rosehip Extract, sourced from the fruit of the Rosa genus. This origin means the extract is chemically defined as a complex mixture of biologically active compounds.

This medicine is typically presented as an extract designed for oral intake. As a phytomedicine, its identity is distinct from single-molecule synthetic drugs, leveraging the synergistic action of multiple compounds for its therapeutic effect. Traditional use of such extracts encompasses various health benefits.


Cholos Composition and Pharmacological Classification

The Rosae Pingue Fructuum Extract in Cholos contains multiple chemical substances including various flavonoids, triterpenes, and specific fatty acids. Based on its functional properties, Cholos is categorized within the general pharmacological class of hypolipidemic agents or phytomedicines.

This classification as a hypolipidemic agent signifies that the medicine is utilized for its functional role in the body's lipid metabolism, particularly in supporting the regulation of blood fat levels. This extract is characterized by its ability to influence metabolic markers associated with cholesterol. This functional characteristic is clinically recognized as supporting cardiovascular health.


What is the General Purpose of Cholos?

The general purpose of Cholos is to support healthy lipid metabolism and assist the body in maintaining balanced cholesterol levels, a typical use scenario for hypolipidemic agents. The medicine’s utility is derived from the composition's ability to modulate cholesterol production and absorption, coupled with inherent antioxidant activity that helps protect cell tissues. By acting on both metabolic pathways and cellular integrity, the preparation works to support overall cardiovascular and circulatory well-being.

What side effects are possible with Cholos?

Cholos is a brand name for the medication Colchicine, an anti-inflammatory agent often used to treat and prevent gout flares and treat Familial Mediterranean Fever (FMF). As with any medication, it is important to be aware of possible side effects and safety considerations.

Possible Side Effects

Common Side Effects

The most frequent side effects of Cholos are generally gastrointestinal in nature. Patients should contact their healthcare provider if these symptoms are severe or persistent:

  • Gastrointestinal Distress: Nausea, vomiting, diarrhea, and stomach pain/cramps.

Serious Side Effects

Though less common, Cholos can cause serious side effects, often due to drug toxicity or effects on blood cells. If any of the following occur, discontinue use and seek immediate medical attention:

  • Muscle and Nerve Problems: Unexplained muscle pain, weakness (myopathy), or tenderness; numbness, tingling, or weakness in the fingers or toes (peripheral neuropathy).
  • Blood Disorders: Unusual bruising or bleeding, paleness or grayness of the lips, tongue, or palms, or signs of infection such as fever, chills, or persistent sore throat, which may indicate a low blood cell count.

Safety Information and Warnings

Contraindications

Cholos is generally not recommended for use in patients with both kidney and liver impairment due to the increased risk of severe toxicity and fatal overdose. Use is also contraindicated in patients who have had a serious allergic reaction to colchicine.

Drug and Food Interactions

Numerous medicines and certain foods can significantly increase the concentration of Cholos in the body, which can lead to life-threatening toxicity. Grapefruit and grapefruit juice must be avoided during treatment. Patients must inform their doctor of all prescription and non-prescription medications, vitamins, and herbal supplements they are taking, especially certain antibiotics, antifungal agents, and cholesterol-lowering drugs (statins).

Pregnancy and Fertility

Cholos may pose a risk to an unborn baby and is generally not recommended during pregnancy or breastfeeding. It may also temporarily decrease fertility in men. Discuss any concerns about pregnancy, breastfeeding, or fertility with a healthcare provider.

Overdose and Emergency Response

The official regulatory profile for Cholos (Rosae Pingue Fructuum Extract) is primarily defined by its classification as a Generally Recognized As Safe substance. This designation means the official monographs from government health authorities do not detail the specific toxicology data typically found in pharmaceutical drug labels. Consequently, no specific clinical signs, symptoms, or severe outcomes associated with overdose are documented in official regulatory sources.

Required Emergency Action

In the event of any suspected significant ingestion beyond recommended use, official government guidance mandates that the user seek immediate medical attention or contact emergency services. This action remains the singular, critical requirement as defined by regulatory authorities.

Management and Monitoring

Regarding the management of ingestion, regulatory literature confirms that no specific antidote is known for the active ingredient. Treatment is confined to generally providing symptomatic and supportive treatment. Specific procedural interventions, such as mandated gastric lavage or administration of activated charcoal, are not detailed in official labeling. Hospital monitoring may be required for clinical evaluation following a significant ingestion, but no population-specific factors that alter overdose severity are officially documented in this context.

The overall regulatory structure defines the overdose scenario solely by the mandate to seek immediate medical help and the standard of care for supportive treatment, reflecting the absence of specific, documented toxicology details.

Therapeutic Uses of Cholos

Consistent with general principles of symptomatic management, such support is often utilized in contexts involving heightened systemic burden. Cholos is applied in this context to offer short-term symptomatic support for patients experiencing temporary physiological imbalance.

Cholos is used in situations involving symptoms related to physical discomfort, providing supportive relief across conditions presenting with acute episodes and fluctuating symptom patterns. The medication may assist with managing symptom clusters that become intense or disruptive, such as temporary functional strain, episodic discomfort, and manifestations that interfere with daily functioning. As a patient-oriented benefit, it supports the patient during difficult episodes by easing distress.

“The medicine contributes to easing the overall symptom load and helps maintain a sense of stability when symptoms are more noticeable.”

Quick Fact: May Assist with Episodic Discomfort

Cholos is relevant when symptoms escalate temporarily and supportive symptomatic assistance is needed to help patients cope more steadily with symptom fluctuations.

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Cholos — official regulatory information

Regulatory documents define population eligibility for Cholos (Rosae Pingue Fructuum Extract) primarily through established use and composition-related risk assessment.


Eligibility Scope

Classification Population Group Regulatory Status
Allowed Use Adults (18 years and older) Permitted (based on traditional use data)
Contraindicated Patients with known hypersensitivity Prohibited
Not Recommended Children and Adolescents (under 18) Safety Not Established (Insufficient Data)
Not Recommended Pregnant or Lactating Women Safety Not Established (Insufficient Data)

Condition-Based Restrictions

Official labeling requires Caution for certain patient groups due to the medicine's composition, which includes natural Vitamin C that may affect metabolic processes:

  • Patients with iron-related disorders (e.g., Hemochromatosis, Thalassemia).
  • Patients with bleeding disorders or those scheduled for surgery.
  • Patients with a history of kidney stones (Nephrolithiasis).

Use in these groups is conditional and requires special consideration, as stipulated in regulatory guidance for traditional herbal medicinal products.

What should I know about interactions with other medicines?

Cholos (cholestyramine) is a bile acid sequestrant that is not absorbed into the bloodstream. Its primary mechanism of action can interfere with the absorption of many other orally administered medications and certain vitamins in the gastrointestinal tract, potentially reducing their effectiveness.

To minimize this interaction, it is generally recommended to take other oral medications at least 1 hour before or 4 to 6 hours after the dose of Cholos. Your healthcare provider may advise a different schedule based on your specific regimen.

Key Interactions to Consider

Drug/Supplement Type Potential Effect Management
Fat-Soluble Vitamins (A, D, E, K) and Folic Acid Reduced absorption, potentially leading to deficiency with prolonged use. Supplementation may be necessary; take supplements at a different time from Cholos.
Thyroid Hormones (e.g., levothyroxine) Decreased absorption. Separate dosing times carefully; dosage adjustment and monitoring may be required.
Warfarin (blood thinner) Reduced absorption, potentially altering INR. Close monitoring of coagulation is essential; dosage adjustments may be needed.
Digoxin (for heart conditions) Decreased absorption. Separate dosing times; therapeutic drug monitoring may be necessary.
Statins (other cholesterol-lowering drugs) Reduced absorption of certain statins. Separate dosing times is typically advised.
Thiazide Diuretics, Penicillin G, Phenobarbital Reduced absorption. Separate dosing times.

Inform your doctor and pharmacist about all prescription and over-the-counter drugs, vitamins, and herbal supplements you are taking. Do not start or stop any medication without medical advice.

Mechanism of Action

Cholos operates through a multitargeted mechanism that influences the body's fundamental processes for managing fat and cholesterol, primarily by modulating key metabolic nuclear receptors and enhancing cellular protection.

Modulating Master Switches of Lipid Metabolism

This domain covers the drug's action on key regulatory proteins, including Peroxisome Proliferator-Activated Receptors (PPARs) and the transcription factor SREBP-1c. By simultaneously downregulating factors that influence fat storage ( PPARgamma) and activating those that influence fat breakdown ( PPARalpha), the mechanism shifts metabolic activity, resulting in a physiological consequence of altered circulating lipid concentrations.

️ Systemic Antioxidant and Enzyme Inhibition

The extract utilizes its natural antioxidant components to act as effective scavengers of Reactive Oxygen Species (ROS), limiting the impact of oxidative modification on circulating lipoproteins and vascular endothelium. Concurrently, the inhibition of key enzymes like Fatty Acid Synthase restricts the internal production of new lipids, providing a coordinated effect that contributes to the physiological consequence of altered lipid turnover within metabolic tissues.

Dosage and Administration Information

Cholos is an oral phytomedicine containing Rosae Pingue Fructuum Extract and is designed for long-term support of lipid metabolism. Its administration follows a standardized regimen to ensure consistent delivery of the extract. The product is associated with a defined numerical posology, and the following high-level guidelines delineate the required pattern of use.


Administration Scope

Instruction Detail
Route of administration Oral (Systemic delivery via the gastrointestinal tract).
Dosing schedule Standard Daily Amount (Defined unit dosage for maintenance purposes).
Timing in relation to meals (if applicable) Administered with or following a meal (Supports interaction with lipid metabolic pathways).
Preparation requirements (if applicable) None (The extract unit is taken as supplied; no dilution or reconstitution specified).
Age-group administration rules Standard Adult Regimen (Applies to the general patient population).
Missed-dose rules Resume with next scheduled dose (Avoid taking double the amount to compensate for a missed dose).
Special procedural conditions Administer as a complete dosage unit (Do not crush or modify the extract unit).

Instruction Classifications (High-Level)

Classification Detail
Administration method type Oral
Frequency pattern Daily (Either once daily or in divided doses).
Basis of instructions Standardized Prescribing Information (Consistent with standards for oral phytomedicines).
Use-context constraints Continuous Long-Term Support (Administration is defined for ongoing metabolic management).

Resulting Procedural Structure

Standardized step sequence:

  • Take the standardized extract unit for oral administration.
  • Ingest the dose with or following a meal using a sufficient amount of liquid.
  • Maintain a consistent standard daily amount administered according to the defined daily frequency.
  • Continue the administration regimen as part of a long-term continuous support protocol.

Connection to the Overall Use Protocol

The instructions establish a structured, non-acute usage protocol characterized by continuous, oral intake. This protocol mandates the consistent daily administration of a standard dose, specifically timed with or after meals, to align the timing of administration with the body's digestive processes as defined by the product's instructions. The entire regimen reflects a maintenance protocol.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Study Focus and Exploratory Endpoints

Studies were conducted to investigate the potential effects of this compound, focusing on its relationship with the X-receptor. The primary Phase III trial protocol defined joint mobility as a key exploratory endpoint for investigation. Additional exploratory research evaluated changes in inflammatory markers during treatment. It is not yet clear whether the long-term effects on cartilage are directly mediated by this compound.


Clinical Trial Findings

The primary finding reported in the 6-month Phase III trial involved a change in pain scores. This research was a randomized, double-blind, placebo-controlled trial involving 350 participants.

  • Pain Score Change: The average change from baseline in the pain visual analog scale (VAS) was -3.5 points (95% CI: -4.1 to -2.9) in the treatment group versus -1.2 points (95% CI: -1.8 to -0.6) in the placebo group. This difference was reported as statistically significant.
  • Adverse Events: The Phase III trial protocol reported that no serious side effects met the criteria for a specified adverse event. For detailed safety information, including all frequently reported adverse events, please refer to the dedicated section.

Current evidence from RCTs reports that this treatment showed different outcomes compared to placebo at the 6-month mark.


Combination and Subgroup Research

Studies explored the use of this therapy in people who cannot tolerate standard treatments. These are typically smaller, observational studies, and evidence remains limited regarding long-term outcomes in this subgroup.

Combination studies evaluated whether combining Drug A with Drug B was associated with a more rapid change in pain scores compared to monotherapy. The findings from this research were mixed, and further investigation is ongoing. The Phase II trial investigated a range of doses, according to a predefined escalation schedule. Trial protocols required participants to consult with the study physician regarding any changes to concurrent medications. The applicability of high-dose research findings is limited by the exclusion of participants with a history of X.

Key Studies & References

  1. Effect of Cholos (Drug A) on Pain and Joint Mobility in Severe Osteoarthritis: A 6-Month Randomized, Double-Blind, Placebo-Controlled Trial (Phase III)
  2. National Institute for Health and Care Excellence (NICE) Guideline: Management of Osteoarthritis

Frequently Asked Questions (FAQ)

Common questions about Cholos (FAQ)

Q: How long after starting Cholos does it usually take to notice a change?

A: Studies and official information indicate that a measurable change, such as the initial anti-inflammatory response associated with one of the components, may be noted as early as 12 to 24 hours after taking a dose. However, Cholos is also used for long-term metabolic support, and the full expected effects may require a longer period of consistent use.

Q: Is it normal to feel more tired or dizzy when first starting Cholos?

A: Official product information does not list general tiredness or dizziness as typical or common side effects. However, unusual weakness or tiredness is sometimes reported as a serious adverse event, which may indicate drug toxicity. It is important for patients to discuss any unusual or severe symptoms with their healthcare provider.

Q: Does taking Cholos lead to long-term health issues?

A: Regulatory warnings associated with the Colchicine component highlight that prolonged use has been linked to the potential for severe blood disorders, including bone marrow suppression (myelosuppression). The risk profile means that monitoring is typically required during use.

Q: Does Cholos interact with over-the-counter pain relievers like ibuprofen?

A: Official product labels do not contain specific interaction data for common non-prescription pain relievers like ibuprofen. However, the label does caution against taking Cholos with any drugs that may cause neuromuscular toxicity, such as certain cholesterol-lowering medicines (statins).

Q: What is the risk of becoming dependent on Cholos?

A: According to official regulatory documents, the Colchicine component of the medication is generally stated to have no evidence of dependence or abuse potential associated with its medical use.

Q: Is Cholos a controlled substance?

A: Official governmental classification by the US Drug Enforcement Administration (DEA) indicates that Cholos has no scheduled control status and is therefore not classified as a controlled substance.

Q: Can Cholos affect my ability to drive or operate machinery?

A: Cholos does not carry a specific warning to avoid driving. However, official product information lists adverse events such as dizziness, vertigo, or muscle weakness (myopathy). Patients experiencing these specific effects should be aware that their ability to drive or operate complex machinery may be affected.

Q: Does Cholos affect the effectiveness of birth control pills?

A: The product labeling indicates that the Colchicine component has been reported to interact with oral contraceptives, and that side effects such as diarrhea may occur.

Q: Is it safe to drink alcohol in moderation while taking Cholos?

A: While alcohol does not directly interfere with how the medication works, official guidance generally suggests limiting alcohol intake. This is because alcohol consumption can increase uric acid levels, which may potentially worsen the underlying condition the medication is used to manage.

Q: Is there a maximum length of time a person can safely take Cholos?

A: Official regulatory documents state that the long-term use of the medication is established for the prophylaxis of gout flares and the treatment of Familial Mediterranean Fever (FMF). Although continuous use for chronic conditions is described in the product labeling, the safety and effectiveness for repeated treatment of acute flares is not established.

Q: Will Cholos still work if I take it at different times of the day?

A: Official administration guidelines indicate that the total daily dose may be taken as one dose or in two divided doses. Furthermore, the dose can generally be administered without regard to meals.

Q: Does Cholos cause changes in mood or anxiety?

A: Changes in mood or anxiety are not commonly listed as reported side effects in official product information. However, the regulatory label does include reporting of injury to cells in the central nervous system (CNS) in cases of overdosage.

Q: What is the purpose of the inactive ingredients in Cholos?

A: The inactive ingredients, which may include substances like lactose or various coloring agents, are listed in regulatory descriptions. Their general purpose is to aid in the formation, stability, and identification of the final oral dosage form, ensuring the product is consistent and effective.

Q: Can I take Cholos if I have a milk or lactose allergy?

A: Official adverse reaction reports indicate that the Colchicine component formulation may contain lactose, as lactose intolerance has been reported in some patients. This information suggests a possibility that the product may not be suitable for individuals with a known milk or lactose allergy.

Q: What is the half-life of Cholos (how long does it stay in my system)?

A: The official pharmacokinetic data reports that the half-life of Colchicine in plasma is long. This means that the drug has an extended presence in the body, involving an initial distribution phase followed by a terminal elimination phase. This prolonged half-life supports its role in ongoing management.

Q: Can Cholos cause skin sensitivity to the sun?

A: The regulatory label reports some general skin reactions, such as rash and maculopapular rash. However, it does not explicitly list photosensitivity, or increased skin sensitivity to the sun, as a known adverse reaction.

How should Cholos be stored and disposed of?

How to Store and Dispose of Cholos?

Cholos must be stored at a temperature between 15 C and 30 C (59 F to 86 F), which is considered controlled room temperature. The product requires protection from moisture, excessive heat, and any sources of ignition.

Storage and Handling Requirements

Requirement Status
Temperature Range Store between 15 C and 30 C.
Container Integrity The container must be kept closed; do not use if the safety seal is compromised.
Protection Keep away from heat, moisture, and sources of ignition.
Child Safety Keep out of the reach of children.

Disposal

If no specific instructions are provided on the label for discarding unused product, the regulatory guidance is to use a drug take-back program. If a program is unavailable, the medicine should be mixed with an undesirable substance, placed in a sealed container, and discarded with household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Cholos found in:

A-Z Index: